Source comparison
Melanotan-1 for UV Protection: Formulation Comparison
Melanotan-1 has been administered under multiple formulations across clinical trials and research applications. Understanding the pharmacokinetic and practical differences is essential for interpreting study results and assessing real-world applicability. Subc
This comparison does not assign a generated winner or score.
- Melanotan-1 has been administered under multiple formulations across clinical trials and research applications. Understanding the pharmacokinetic and practical differences is essential for interpreting study results and assessing real-world applicability.
- Subcutaneous Implant (Scenesse)
- 16mg controlled-release
- ~60 days
- Subdermal insertion by clinician
- FDA-approved for EPP; maintains steady plasma levels
- Gold standard for photoprotection in EPP. Steady release eliminates compliance issues
- Daily Subcutaneous Injection
- 0.16mg/day loading, 0.08–0.16mg maintenance
- Indefinite (requires daily adherence)
- Self-administered injection
- Phase II trials; used in off-label contexts
- Effective but requires strict adherence and proper storage; higher GI side effect incidence
- Intranasal Spray (discontinued formulation)
- 8–20mg per spray
- Transient (~4 hours)
- Nasal mucosa absorption
- Evaluated in Phase I; poor bioavailability
- Abandoned due to inconsistent absorption and minimal melanogenic response
- The implant formulation is unambiguously superior for clinical photoprotection. Patient compliance is guaranteed, plasma levels remain within the therapeutic window, and the controlled-release matrix prevents the nausea associated with bolus dosing. Daily injection protocols require meticulous reconstitution, cold-chain storage, and injection technique, making them impractical for long-term use outside research settings.